GURUFOCUS.COM » STOCK LIST » USA » NAS » Pyxis Oncology Inc (NAS:PYXS) » Definitions » Other Operating Expense
Switch to:

Pyxis Oncology (NAS:PYXS) Other Operating Expense

: $-0.00 Mil (TTM As of Dec. 2022)
View and export this data going back to 2021. Start your Free Trial

Pyxis Oncology's Other Operating Expense for the three months ended in Dec. 2022 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.00 Mil.

Pyxis Oncology's quarterly Other Operating Expense increased from Jun. 2022 ($-0.00 Mil) to Sep. 2022 ($0.00 Mil) but then declined from Sep. 2022 ($0.00 Mil) to Dec. 2022 ($0.00 Mil).

Pyxis Oncology's annual Other Operating Expense declined from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($-0.00 Mil) and declined from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($-0.00 Mil).


Pyxis Oncology Other Operating Expense Historical Data

The historical data trend for Pyxis Oncology's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Other Operating Expense
- - - -

Pyxis Oncology Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Other Operating Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pyxis Oncology Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pyxis Oncology Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Pyxis Oncology (NAS:PYXS) Business Description

Pyxis Oncology logo
Traded in Other Exchanges
N/A
Address
35 CambridgePark Drive, Cambridge, MA, USA, 02140
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Executives
Pfizer Inc 10 percent owner 235 E 42ND ST, NEW YORK NY 10017
Pfizer Ventures (us) Llc 10 percent owner 235 EAST 42ND STREET, NEW YORK NY 10017
Rachel Humphrey director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Jitendra Wadhane officer: SVP, Chief Accounting Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin other: Former Director 20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Yanchik Connealy Pamela officer: Chief Financial Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Bayer World Investments B.v. 10 percent owner ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst officer: Chief Scientific Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Jay Feingold officer: Chief Medical Officer C/O PYXIS ONCOLOGY, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Ritu Shah officer: Chief Operating Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
John L Flavin director C/O MEDICHEM LIFE SCIENCES INC, 12305 SOUTH NEW AVENUE, LEMONT IL 60439

Pyxis Oncology (NAS:PYXS) Headlines